Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Former FDA Commissioner Robert Califf has spoken out as layoffs continue at the FDA, with the latest cuts affecting the Center for Drug Evaluation and Research (CDER). The layoffs are part of a larger reduction of 10,000 jobs at the Department of Health and Human Services. In addition, biopharma markets are in chaos following the departure of Peter Marks from the FDA's Center for Biologics Evaluation and Research (CBER).Carisma Therapeutics has laid off most of its staff and is considering selling off assets and winding down fully. Analysts are calling for President Donald Trump to reconsider his appointment of Robert F. Kennedy Jr. as Secretary of Health and Human Services. The departure of Peter Marks from the FDA has caused shares in the biopharma markets to tumble.Trilink offers custom guide RNAs (grRNAs) for CRISPR-based therapy discoveries. Despite market challenges, the cell and gene therapy sector has seen a 30% investment surge. Companies like Tenaya are cutting their workforce to fund development of gene therapies.Overall, the biopharma industry is facing uncertainty and instability as layoffs continue and key figures depart from regulatory agencies.